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Abstract
The impending expiry of the patent on a number of leading biologic drugs has led to a surge in the
development of ‘biosimilar’ or ‘follow-on’ products. However, in contrast to generic small-molecule
medicines, biosimilars are not identical to their reference products. The differences and complexities
surrounding both the molecular structure and the manufacturing process for biologics and biosimilars
have resulted in a lack of clarity regarding the terms used in different parts of the world to define
various aspects of development and utilization such as regulatory approval, pharmacovigilance,
interchangeability and treatment-naivety. This makes quantitative evaluation of biosimilars a great
challenge to both the scientific community and regulatory agencies.
This manuscript attempts to clarify the terms used and address an important knowledge gap which is
currently resulting in an increasing rush to position biosimilars for certain indications and patients in the
absence of agreed upon definitions.
Introduction
The impending expiry of the patent on a number of leading biologics has led to a
recent surge in the development of ‘biosimilar’ or ‘follow-on’ products1.
However, in contrast to generic small-molecule medicines, biosimilars are not
‘identical’ to their reference product1. The complexity and heterogeneity of the
molecular structure and the complicated manufacturing process make informed
evaluation of biosimilars a great challenge to both the scientific community and
regulatory agencies2.
Use of biosimilar products has the potential to decrease the cost of treatment
in many regions of the world, in turn making it accessible to many more patients.
It is expected that the use of biosimilars will reduce pharmaceutical costs by
20–30% on average. With several top-selling biologics likely to lose patent
exclusivity by 2020, bodies such as health insurers, regulatory agencies,
reimbursement organizations and pharmaceutical and biotech companies are
preparing for the availability of new biosimilars by addressing formulary
management and therapeutic interchange issues, pharmacovigilance and
patient safety concerns, and related financial and operational issues3.
A regulatory pathway for approval of these products has now been firmly
established in Europe with over 20 biosimilars (of six originator biologics)
being approved since 2006. In the meantime many other countries have estab-
lished the appropriate regulatory pathways for biosimilars, currently resulting in
the approval of eight biosimilars in Australia, three in Canada, seven in Japan,
three in Korea and one in the US. Despite this many clinicians are reluctant to
consider biosimilars as a treatment option for their patients. Major concerns
voiced about biosimilars relate to their pharmaceutical quality, safety (especially
immunogenicity) and efficacy (particularly in extrapolated indications)4.















































































































Lack of awareness and information regarding these
agents is a significant problem5. A study conducted in
2011 of 277 healthcare professionals (HCPs) indicated
that 26%, 21% and 31% of pharmacists, physicians and
nurses respectively, needed more information before
making a decision about using biosimilars6. Respondents
stated that evaluations which compared the chemical,
physical and pharmacokinetic similarities of biosimilars
and their reference products, plus safety and efficacy data
were among the most important types of information they
needed. In a separate survey, more than 57% of hospital
pharmacists stated that confirmatory clinical trials
comparing biosimilars to the branded originator biologic
in each indication for which approval is sought, were
necessary to prove biosimilarity7.
Currently, it is generally accepted that biosimilars are
most appropriately initiated in treatment-naı¨ve patients,
although definition of this is open to interpretation as no
clear guidelines exist on this.
This manuscript attempts to address an important
knowledge gap which is currently resulting in an increas-
ing rush to position biosimilars for treatment-naı¨ve
patients in the absence of agreed upon definitions of
naı¨vety per molecule and per indication.
Regulatory approval of biosimilars
The European Medicines Agency (EMA) was the first
to establish the regulatory and scientific concepts for bio-
similars8. Since then, implementation of the regulations
has evolved with many other countries establishing
their own national guidelines, but the definitions and
terminology for biosimilarity vary9,10.
The approval process for a biosimilar may be abridged
with respect to the non-clinical and clinical requirements
on the conditions that its physicochemical and in vitro
functional properties have been shown to be highly similar
to an already approved reference product10. However, this
means that the amount of available clinical efficacy and
safety data for the biosimilar will be less than that for an
original product11. To cover this gap in the abbreviated
approval pathway, and also to clarify any uncertainty
regarding extrapolated indications, it is obligatory for
biosimilar manufacturers to submit comprehensive phar-
macovigilance plans when applying for approval8.
Pharmacovigilance and traceability
An important concern with all biologic medicines is the
potential for an unwanted immune response, thus the abil-
ity to track and trace such events is critical12,13. The WHO
program for international drug monitoring is based on the
principle of international collaboration in the field of
pharmacovigilance. Over 100 member nations have sys-
tems in place that encourage HCPs to record and report
adverse drug reactions14.
Recently, new European pharmacovigilance legislation
has been implemented which focuses on those medicines
(both innovator biologics and biosimilars) that require
additional monitoring, ensuring proper risk management
through the recording of suspected adverse drug reactions
and data collection from all stakeholders15. The new regu-
lation entails a reduction of the administrative burden on
companies and regulatory agencies, as obligations are
clearly established and duplication of effort avoided16.
These new guidelines impose the recording of the brand
name and batch number. For biosimilars a ‘black triangle’
must be included in the product information to indicate
that it is subject to additional monitoring as with new
biologicals. A list of the EU-approved biosimilars currently
requiring additional monitoring is shown in Table 116.
Pharmacovigilance of biologics and biosimilars should
include processes that are easily used by prescribing prac-
titioners to ensure that data are consistent and new safety
signals are properly reported and assigned to the correct
product17. Such surveillance can be accomplished by many
means, including implementing patient registries and/or
prospective or retrospective observational and epidemio-
logical studies18. However, as with any patient registry
data, the information is only as accurate as it is entered
into a registry and could be misleading. Furthermore,
the question remains as to how registries for the same indi-
cation from different countries can be pooled and analyzed
to enable sufficient data for complete evaluation.
However post-marketing surveillance is conducted, it
would be helpful for the international non-proprietary
name (INN) to be recognized all over the world. Because
generic chemical drugs are automatically assigned the
same non-propriety name as the branded agent recognition
is very straightforward, but the naming process for biosi-
milars is likely to be less so. Even though discussions are
still ongoing as to whether the INN of a biosimilar should
be distinct from that of the original biological, current
practice in the EU is that the INN of a new biosimilar
may be the same as that of the original biologic. Using
the INN for prescription purposes will inevitably lead to
situations in which the prescribing physician will not know
to which medicine any adverse event data refers to. This
may lead to the erroneous interpretation of a class effect
when in fact the reference product (or indeed a biosimilar)
may not be responsible. It is therefore strongly encouraged
to prescribe biologicals in general and biosimilars in par-
ticular by brand name rather than INN19 and the medical
records should be accurate as to what product the patients
receive.
This naming issue has recently prompted the World
Health Organization to propose a new system of ‘biological
qualifiers’ (BQs) to ensure that biosimilars can be more
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easily distinguished from their biologic counterparts.
The BQ proposal suggests adding a unique four-letter
code to complement the INN of a biological substance
manufactured at a specific site with the aim of more
easily identifying both the manufacturer and potentially
the manufacturing site of the active substance20. It is ques-
tionable however as to what added value the addition of
a BQ to the INN will provide to the traceability of a
drug product, compared to the use of the brand name
and batch number.
Interchangeability
Approval of a biosimilar does not mean that the medica-
tion is interchangeable with its reference product21.
Because the regulatory pathway for biosimilars is abbre-
viated the available clinical efficacy and safety data are
more limited than for their reference products21.
According to the FDA a biosimilar product is a bio-
logical product that is approved based on it showing that
it is highly similar to an FDA-approved biological product,
known as a reference product, and has no clinically mean-
ingful differences in terms of safety and efficacy from the
reference product. An interchangeable biological product
is biosimilar to an FDA-approved reference product and
meets additional standards for interchangeability that
include the same expected result in any given patient
and no increased risks or decreased efficacy with multiple
switches. Such an interchangeable biological product may
be substituted for the reference product by a pharmacist
without the intervention of the healthcare provider who
prescribed the reference product22.
In Europe substitution policies are decisions outside the
remit of the EMA because the regulation of substitution of
medicinal products is the responsibility of the individual
EU member states4. Long-term clinical investigations and
systematic monitoring of the efficacy and tolerability of
biosimilars in all indications are still needed23, and even
then establishing the interchangeability of biosimilar
and innovator drugs will be difficult. Although it hasn’t
happened so far, it is possible in the future that some bio-
similars might not carry the same indications as those for
which the reference drug is approved3.
Furthermore, individual countries outside the EU may
exercise their own discretion with regard to the approval of
biosimilars (and indeed other original medicinal products)
for all the indications assigned to the originator drug. For
example, two brands of the monoclonal antibody inflixi-
mab (IFX) from the Korean company Celltrion were
approved as ‘subsequent entry biologics’ in Canada in
January 2014 for some (but not all) approved indications
for the existing brands. Inflectra/Remsima received two
psoriasis indications (psoriasis and psoriatic arthritis)
from extrapolation of the clinical data beyond the
foundation indications for rheumatoid arthritis (RA) and
ankylosing spondylitis. These ‘extrapolated’ approvals,
however, did not extend to Crohn’s disease and ulcerative
colitis because the mode of action in this therapeutic
area is potentially different from the mode of action in
RA and ankylosing spondylitis24.
The distinction between a designation of ‘biosimilar’
and ‘interchangeable’ is important, particularly when it
comes to formulary decisions25. This situation is further
complicated by the fact that a declaration of biosimilarity
emphatically does not imply that a patient could be
Table 1. List of EU-approved biosimilars currently requiring additional monitoring*,16.
Name Active substance Therapeutic area Date of authorization
Accofil filgrastim Neutropenia 18/09/2014
Abasaglar (previously Abasria) insulin glargine Diabetes mellitus 09/09/2014
Bemfola follitropin alfa Anovulation 27/03/2014
Grastofil filgrastim Neutropenia 18/10/2013
Ovaleap follitropin alfa Anovulation 27/09/2013














*Biosimilars authorized after 1 January 2011. Medicines under additional monitoring have a black inverted triangle displayed in
their package leaflet and summary of product characteristics, together with a short sentence explaining what the triangle means.
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switched from one product to another26. Switching means
transitioning between the reference product and the
biosimilar (or vice versa). Interchangeability refers to
switching back and forth between the reference product
and the biosimilar, and substitution is interchanged
without the knowledge of the prescribing physician.
The FDA states that interchangeability should be
proven by a clinical trial that shows no loss of efficacy
and no increase in adverse events with repeated switching
between the biosimilar and the reference compound22.
However, the design of a clinical trial to prove this
might be controversial. The experimental group would
have to be switched repeatedly between the reference
product and the biosimilar, whereas the control
group would be treated with the reference product or the
biosimilar alone. Without any prior understanding of the
consequences from previous studies the experimental
group might be at risk of loss of efficacy and/or increased
safety concerns.
The Norwegian Medicines Agency is proactively
encouraging a substitution culture and have initiated a
clinical study to investigate the safety and efficacy of
switching between IFX (Remicade) and the biosimilar
Remsima in patients with RA, spondyloarthritis, psoriatic
arthritis, ulcerative colitis, Crohn’s disease and chronic
plaque psoriasis (ClinicalTrials.gov identifier:
NCT02148640)27. The primary endpoint of the NOR-
SWITCH study is the occurrence of disease worsening in
the indications being studied27. However these endpoints
cannot actually be analyzed (pooled) together and
the sample size in each disease is underpowered to show
a difference if it exists.
In France, a new law (beginning on 1 January 2014 but
as yet to be implemented by decree) states that pharmacists
will be legally permitted to substitute a biosimilar for the
prescribed reference biological medicine as long as the
prescribing physician has not marked the prescription as
‘non-substitutable’28. Importantly, substitution will be
allowed only when initiating a course of treatment, and
if the biosimilar belongs to the same group as the pre-
scribed product, known as a ‘similar biologic group’. If
the pharmacist decides to substitute a biosimilar for the
prescribed biologic, he/she must both write the brand
name of the dispensed product on the prescription and
inform the prescribing physician in order to maintain an
accurate medical record. These laws remain to be further
defined in decrees from the Administrative Supreme
Court, and thus biosimilar substitution should only occur
in French practice after these decrees have been adopted28.
Confusion around switching and the interchangeability
of biosimilars is further complicated by the fact that HCPs
may not only need to make decisions about changing from
an original biological to a biosimilar, but at some point in
the future may also need to consider a switch in the oppos-
ite direction, from biosimilar to original, or even from
biosimilar #1 to biosimilar #2 when two or more (inde-
pendently developed) biosimilars come onto the market.
Moreover, that decision may need to be reconsidered
further over time as product drifts occur. It is important
to realize that biosimilarity is only assured at the time of
approval and there is no guarantee that biosimilarity or
interchangeability is fully maintained during the lifecycle
of reference and biosimilar.
Which patients, and when, to treat with
biosimilars?
Switching options may be narrowed down by the limita-
tion of which patients are appropriate targets for treatment
with a biosimilar – naı¨ve or transitioning patients. The
definition of naı¨vety in this context is not clearly defined
and interpretation may vary from country to country.
For example, the Italian Medicines Agency (AIFA)
have assigned the term ‘naı¨ve’ to two specific categories:
(i) patients with no previous therapeutic exposure to ori-
ginator (‘primary naı¨ve’), and (ii) patients with previous
exposure to the originator but with a wash-out period of
time adequately long based on the judgment of the clin-
ician (‘secondary naı¨ve’)29,30. However, there are potential
variables affecting the washout period such as the drug
biologic effect itself and its immunogenicity, and therefore
the term ‘secondary naı¨ve’ can be subject to different
interpretations29,30.
Absolute naı¨vety in the current context should be
defined as ‘no prior treatment with the reference or
respective biosimilar’. However, it may be more appropri-
ate and valuable to define those patients suitable for treat-
ment with a biosimilar drug on a therapy-area basis, based
on the volume and quality of the available post-marketing
evidence.
For example, the biosimilars currently approved in
oncology are used for the treatment of chemotherapy-
induced anemia (biosimilar epoetins) and prevention of
chemotherapy-induced neutropenia (biosimilar filgras-
tims). As a result of the extensive post-marketing studies
conducted to address potential safety issues, patient expos-
ure to these biosimilars is increasing31. As of April 2013
estimated exposure to Binocrit (a biosimilar epoetin
alpha) is over 216,000 patient-years, with more than
5000 patients studied in clinical trials31. The current esti-
mated exposure to Zarzio (a biosimilar filgrastim) is 3.5
million patient-days31. A recent review of biosimilar
epoetins identified no difference in safety profiles between
biosimilar and reference products, or between the alterna-
tive biosimilar formulations32. Similarly, a prospective,
randomized controlled trial, conducted since licensing,
has shown equivalence in pharmacokinetic and pharma-
codynamic profiles, safety and clinical efficacy between
Current Medical Research & Opinion Volume ??, Number ? Month?? 2015















































































































originator and biosimilar epoetins33. However this should
not be interpreted as being applicable to all epoetins and
all routes of applications. Indeed, for Binocrit, the subcuta-
neous route of administration has not been approved
because of immunogenicity concerns34.
Whilst the experience with rather small biosimilars,
such as epoetins, has generally been positive, concerns
have arisen about the efficacy and safety of CT-P13 (the
anti-tumor necrosis factor IFX biosimilar), the extrapola-
tion of results from rheumatologic trials to inflammatory
bowel disease (IBD) and the interchangeability of CT-P13
with its reference product, Remicade35. The clinical
biosimilarity of CT-P13 with its reference drug was
established in a pharmacokinetic study of patients with
ankylosing spondylitis36 and in an efficacy study in
patients with RA37. However, many physicians who treat
patients with IBD still oppose extrapolation from other
indications due to differences in mechanism of action asso-
ciated with membrane-bound TNF in IBD compared with
soluble TNF in the arthridites35,38.
Extrapolation of indications for biosimilar
antibodies?
The issue of extrapolation of data for indications of the
originator drug which are not tested in the biosimilar is a
difficult one. The assumption that no additional safety
issues are expected for the extrapolated indication (based
on the same mode of action) cannot always be considered
automatically sufficient, particularly when the different
indications involve the use of different dosages or target
population39. For example the safety and immunogenicity
may not be fully established if the study population is
immune-compromised, and then extrapolated to a more
immune-competent population.
Indeed translating treatment outcomes from one setting
to another is not a foregone conclusion even with original
biologics, as evident from the ALTTO trial in HER2-
positive breast cancer40. Despite the promising results
from an earlier trial which showed that the combined
use of lapatinib and trastuzumab doubled the pathologic
complete response rate compared with trastuzumab alone,
there was no difference between the same two arms in
a subsequent larger trial (8381 randomized patients) con-
ducted in the adjuvant setting40. This clearly demonstrates
that the results from trials in a specific setting/study
population cannot always be extrapolated to a different
study population unless corroborated by clinical trial
data in that specific population.
The European Crohn’s and Colitis Organisation
(ECCO) position statement states that a biosimilar
proven effective and safe for one indication may not neces-
sarily be effective and safe for a second indication in which
the reference biological has been shown to be safe and
effective41. ECCO advocates the need for a robust
trial in patients with IBD to establish its efficacy
and safety for this condition. The Spanish Society of
Gastroenterology task force also stated that results from
studies in patients with RA should not be extrapolated
to patients with IBD42.
Conclusions
A lack of understanding amongst HCPs with the rapidly
growing entry of biosimilars into the market inevitably
leads to some clinical concerns. However, as the level of
safety and efficacy data increases over time, so will the rou-
tine use of biosimilars across numerous therapy areas with a
shift from simple biosimilar molecules in supportive care to
complex biosimilar drugs for lifesaving or life-extending
treatments.
The difference between biosimilarity, interchangeabil-
ity and switching is still not clearly understood and is likely
to become even more complex as newer biosimilar agents
emerge. As yet, no guidance exists as to how this should be
managed.
It is important that HCPs receive adequate education
about biosimilars and that standardized terminology and
nomenclature are established to enable adequate and
effective introduction of biosimilars in healthcare, which
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